Overview

A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

Status:
Not yet recruiting
Trial end date:
2024-10-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in patients with mid-portion Achilles tendinopathy.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals